Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here the info!
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Outstanding? and Authorized?
What Are Shares Outstanding? https://www.investopedia.com/terms/o/outstandingshares.asp
What is Authorized Shares?
https://www.investopedia.com/terms/a/authorizedstock.asp
Outstanding? and Authorized?
What Are Shares Outstanding? https://www.investopedia.com/terms/o/outstandingshares.asp
What is Authorized Shares?
https://www.investopedia.com/terms/a/authorizedstock.asp
PATENT INFORMATION
======================================
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=86202825
Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.
MultiCell Technologies, Inc.
US Patent 6,737,057: Compounds, compositions and methods for the Endocytic presentation of immunosuppressive factors
US Patent 6,129,911: Liver stem cell
US Patent 6,872,389: Liver stem cell
US Patent 6,017,760: Isolation and culture of porcine hepatocytes
US Patent 6,107,043: Immortalized hepatocytes
US Patent 5,043,260: Perfusion device with hepatocytes
US Patent 4,795,459: Implantable Prosthetic Device (endothelial)
US Patent 6,858,146: Artificial Liver Apparatus and Method (Trademarked as the SybiolR synthetic bio-liver)
US Patent 7,935,528 The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
US Patent 7,566,567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1685252A4: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
WO05034876A2 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2541380A1 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Xenogenics.
When Xenogenics acquired the assets of Bioabsorbable Therapeutics, Inc., it acquired and continues to support issued U.S. patent 7,674,285: Polyanhydride polymers and their uses in biomedical devices. This process is incorporated in and trademarked as the Ideal Bio-StentR.
MultiCell ImmunoTherapeutics.
Below is a listing of the intellectual properties of which Astral, Inc. is the Assignee. This intellectual property is now owned by MultiCell Immunotherapeutics resulting from the purchase agreement between MultiCell Technologies, Inc. and Alliance Pharmaceuticals, Inc.
US20120189645A1:COMPOSITIONS AND METHODS TO TREAT AND CONTROL TUMORS.
CN100376594C: DOUBLE-CHAIN RNA AND METHOD TO INITIATE, ENHANCE OR ADJUST IMMUNOMODULATORY OR IMMUNE RESPONSE.
CN1795274A: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1780848A: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND
MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
WO04087877A3: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CN1703427A: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS .
WO04087877A2: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
WO04027049B1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO04027049A3: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595B1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
WO04027049A2: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A3: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
CA2520181A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
CA2499066A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
AU4225480A1: SELECTED RNA MOTIFS TO INCLUDE CELL DEATH AND/OR APOPTOSIS.
AU3276932A1: METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF TCELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS.
WO03078595A2: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY
USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
CA2479187A1: IMMUNOSTIMULATORY DOUBLE STRANDED RNA AND METHODS OF INDUCING, ENHANCING OR MODULATING THE IMMUNE RESPONSE.
AU3218181A1: COMPOSITIONS AND METHODS TO INITIATE OR ENHANCE ANTIBODY AND MAJOR-HISTOCOMPATIBILITY CLASS I OR CLASS II-RESTRICTED T CELL RESPONSES BY USING IMMUNOMODULATORY, NON-CODING RNA MOTIFS.
US7566567: Immortalized hepatocytes
US20070104696A1: Use of cell lines to produce active therapeutic proteins
US20070004039A1: Immortalized hepatocytes
EP1704227B1:
IMMORTALIZED HEPATOCYTES
DE602004025380C0: IMMORTALISIERTE HEPATOZYTEN
AT0456376E: IMMORTALISIERTE HEPATOZYTEN
AU8229981A1: Immortalized hepatocytes
AU4322811AH: Immortalized hepatocytes
EP1704227A4: IMMORTALIZED HEPATOCYTES
WO06041488C1: IMMORTALIZED HEPATOCYTES
WO06041488A1: IMMORTALIZED HEPATOCYTES
IL0174787A0: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1685252A4: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
EP1704227A1: IMMORTALIZED HEPATOCYTES
EP1685252A2: USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2550452A1 IMMORTALIZED HEPATOCYTES
AU4322811A1 Immortalized hepatocytes
WO05034876A3 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
WO05034876A2 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
CA2541380A1 USE OF CELL LINES TO PRODUCE ACTIVE THERAPEUTIC PROTEINS
AU4280238AB Use of cell lines to produce active therapeutic proteins
AU4280238A1 Use of cell lines to produce active therapeutic proteins
Four Fa2N-4 Multicell Technologies / Xenotech Patents Active!
>>>>> Immortalized hepatocytes and Use of cell lines to produce active therapeutic proteins <<<<<
3 Patents: US 7566567 B2 2025-01-13, EP 1704227 B1 2024-10-07, DE 602004025380 D1 2024-10-08. Immortalized hepatocytes
https://patentimages.storage.googleapis.com/f4/60/29/ede269c0aa7f25/US7566567.pdf
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2
Doc Type: Granted Patent
ID: lens.org/167-627-709-236-287
Jul 28, 2009
Application US10/574,163 events 2003-10-10 - Application granted Status Active 2025-01-13
https://patents.google.com/patent/US7566567B2/un
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1
Doc Type: Granted Patent
ID: lens.org/097-040-197-694-101
Jan 27, 2010
Application EP04794437A events 2003-10-10 - Publication of EP1704227B1 Status Active 2024-10-07
https://patents.google.com/patent/EP1704227B1/en
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1
Doc Type: Granted Patent
ID: lens.org/082-791-344-403-259
Mar 18, 2010
Application DE602004025380T events 2003-10-10 - Publication of DE602004025380D1 Status Active 2024-10-08
https://patents.google.com/patent/DE602004025380/D1
1 Patent US20070004039A1 Use of cell lines to produce active therapeutic proteins
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
Application US10/574,163 events
2003-10-10 Priority to US51050903P
2004-10-07 Application filed by Multicell Technologies Inc
2007-01-04 Publication of US20070004039A1
2009-07-28 Publication of US7566567B2
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?assignee=multicell+technologies&oq=multicell+technologies
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
There are now four Active Patents Found From Multicell Technologies and Xenotech. Detailed information will come soon.
There will be more information later.
MCET SECURITY DETAILS Share Structure Take a close look!!!!!!!!!
https://www.otcmarkets.com/stock/MCET/security
AS and OS!!!!!!!!!!!
How much??????????????
No idea!
Great! Second Patent of Multicel Technologies and Xenotech ACTIVE!
Patent US20070004039A1 Use of cell lines to produce active therapeutic proteins
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
Application US10/574,163 events
2003-10-10 Priority to US51050903P
2004-10-07 Application filed by Multicell Technologies Inc
2007-01-04 Publication of US20070004039A1
2009-07-28 Publication of US7566567B2
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?assignee=multicell+technologies&oq=multicell+technologies
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
Published online 2020 Mar 17
3.3.4.2. RNA-based agonists
MCT465, developed by MultiCell Technologies Inc., is a high molecular weight synthetic double-stranded RNA (dsRNA) designed to activate the innate immune system through TLRs 3/7/8 signaling. with immune enhancing properties. In preclinical studies, MCT-465 successfully reduced pulmonary influenza virus levels 1,000-fold in animal models. It also demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT465 is currently ongoing preclinical trials for liver cancer (hepatocellular carcinoma), breast cancer (triple-negative breast cancer TNBC), and others [259]. According to the company, MCT-465 could be indicated as cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be combined with MCT-475, a patent pending antigen-presenting immunoglobulin therapeutic, for the treatment of various cancers such as breast and metastatic colorectal carcinoma.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173040/
$MCET looks good! On BB!
$MCET Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
$MCET Multicell Technologies raised at what price ??? Because of the ...
Fact Number 1:
Form 15-12G Filing Date 2017-01-13 Rule 12g-4(a)(2) [X]
Common Stock, Par Value $0.01 Per Share
https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
Fact Number 2:
Changes to Exchange Act Registration Requirements to Implement Title V and Title VI of the JOBS Act
https://www.sec.gov/info/smallbus/secg/jobs-act-section-12g-small-business-compliance-guide.htm
Fact Number 3:
Eide Bailly LLP says MCET up and down ???
DEF 14A Filing Date 2014-12-12
https://www.sec.gov/Archives/edgar/data/811779/000114420414073653/v396431_def14a.htm
Authorized Shares 10,000,000,000 12/02/2020
https://www.otcmarkets.com/stock/MCET/security
Fact Number 4:
More accurate Granted Patent Drug names are called: IFH15, IFHP.06, IFHP.12, IFHP.24, IFHP.48, IFHP.96 ( CYP1A2, CYP2B6, CYP2C9, CYP3A4! Multicell Technologies Immortalized Hepatocytes Doc Type Granted Patent in US, Europe and Germany! )
Immortalized Human Hepatocyte Cell Lines
[0084]In another preferred embodiment of the present invention, the cell lines proliferate easily in media. Preferably, the cell lines proliferate easily in a serum-free media. More preferably, the cell lines proliferate easily in MFE media (MultiCell Technologies Inc., Providence, R.I., USA; XenoTech, LLC, Lenexa, Kans., USA). https://www.lens.org/lens/patent/167-627-709-236-287/fulltext
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160160735
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160155674
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160156621
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160258239
Fact Number 5:
Multicell is silent about this filing. 2017-01-13 Rule 12g-4(a)(2)
Common Stock, Par Value $0.01 Per Share https://www.sec.gov/Archives/edgar/data/811779/000149315217000429/form15-12g.htm
$MCET BREAKOUT ALERT! New High ALERT! VOLUME ALERT!
$MCET BREAKOUT ALERT! New High ALERT! VOLUME ALERT!
This belongs to Multicell Technologies! Patent Active to: US 7566567 B2 2025-01-13, EP 1704227 B1 2024-10-07, DE 602004025380 D1 2024-10-08.
https://patentimages.storage.googleapis.com/f4/60/29/ede269c0aa7f25/US7566567.pdf
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2
Doc Type: Granted Patent
ID: lens.org/167-627-709-236-287
Jul 28, 2009
Application US10/574,163 events 2003-10-10 - Application granted Status Active 2025-01-13
https://patents.google.com/patent/US7566567B2/un
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1
Doc Type: Granted Patent
ID: lens.org/097-040-197-694-101
Jan 27, 2010
Application EP04794437A events 2003-10-10 - Publication of EP1704227B1 Status Active 2024-10-07
https://patents.google.com/patent/EP1704227B1/en
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1
Doc Type: Granted Patent
ID: lens.org/082-791-344-403-259
Mar 18, 2010
Application DE602004025380T events 2003-10-10 - Publication of DE602004025380D1 Status Active 2024-10-08
https://patents.google.com/patent/DE602004025380/D1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
Patent active to: US 7566567 B2 2025-01-13, EP 1704227 B1 2024-10-07, DE 602004025380 D1 2024-10-08.
Multicell Patent US 7566567 B2 Immortalized Human Hepatocyte Cell Lines: GOVERNMENT GRANTS
This invention was made in part with United States government support under grant number 70-NANB7H3070 awarded by Advanced Technology Program of the United States Department of Commerce. The U.S. government has certain rights in this invention.
All info about Patent US 7566567 B2: http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7566567
Multicell Technologies Inc has 6 trademark applications.
https://uspto.report/company/Multicell-Technologies-Inc
UPDATED How to obtain a NATO Commercial and Government Entity (NCAGE) Code (English)
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$MCET 6s BOOOM! Buy ATTACK! Over 100M Volume! New High!
$MCET 6s BOOOM! Buy ATTACK! Over 100M Volume! New High!
$MCET Hit 6s goes up! BOOM...
$MCET Hit 6s goes up! BOOM...
$IDGC 0.0012 +50.00% Volume: 562,201,457 Nice up!
$IDGC 0.0012 +50.00% Volume: 562,201,457 Nice up!
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET AND: Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET AND: Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET $$$$$ Question: How many units of the drugs are sold to hospitals each year? US and Europe / Germany patents have approximately 8146 hospitals in total.
There are around 2.000 hospitals (Krankenhäuser) in Germany. https://www.iamexpat.de/expat-info/german-healthcare-system/hospitals-germany#:~:text=There%20are%20around%202.000%20hospitals,of%20health%20insurance%20you%20have.
Total Number of All U.S. Hospitals 6,146 https://www.aha.org/statistics/fast-facts-us-hospitals
$631 Dollar average price of 6 drugs https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161097767
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
$MCET $$$$$ Question: How many units of the drugs are sold to hospitals each year? US and Europe / Germany patents have approximately 8146 hospitals in total.
There are around 2.000 hospitals (Krankenhäuser) in Germany. https://www.iamexpat.de/expat-info/german-healthcare-system/hospitals-germany#:~:text=There%20are%20around%202.000%20hospitals,of%20health%20insurance%20you%20have.
Total Number of All U.S. Hospitals 6,146 https://www.aha.org/statistics/fast-facts-us-hospitals
$631 Dollar average price of 6 drugs https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161097767
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
$MCET Multicell Patent US 7566567 B2 Immortalized Human Hepatocyte Cell Lines: GOVERNMENT GRANTS
This invention was made in part with United States government support under grant number 70-NANB7H3070 awarded by Advanced Technology Program of the United States Department of Commerce. The U.S. government has certain rights in this invention.
All info about Patent US 7566567 B2: http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7566567